Promises of a biocompatible nanocarrier in improved brain delivery of quercetin: Biochemical, pharmacokinetic and biodistribution evidences

International Journal of Pharmaceutics

Volumn 515, Issue 1-2, 2016, Pages 307-314

  Kumar, Pramod ^a   Sharma, Gajanand ^b   Kumar, Rajendra ^c   Singh, Bhupinder ^b,c   Malik, Ruchi ^a   Katare, Om Prakash ^b   Raza, Kaisar ^a  

^a CENTRAL UNIVERSITY OF RAJASTHAN   (India)

^b PANJAB UNIVERSITY   (India)

^c PANJAB UNIVERSITY   (India)

Author keywords

Bioavailability; Nanoparticles; Neurological disorders; Neuroprotection; NLCs; SLNs

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; GLUTATHIONE; LIPID PEROXIDASE; NANOCARRIER; PHOSPHOLIPID; QUERCETIN; SOLID LIPID NANOPARTICLE; BIOMATERIAL; DELAYED RELEASE FORMULATION; DRUG CARRIER; LIPID; NANOMATERIAL; NANOPARTICLE;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; CACO 2 CELL LINE; CHEMICAL COMPOSITION; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DPPH RADICAL SCAVENGING ASSAY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG STABILITY; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOENCAPSULATION; NANOFABRICATION; NANOPHARMACEUTICS; NONHUMAN; OXIDATIVE STRESS; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; BIOAVAILABILITY; BRAIN; CACO-2 CELL LINE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; MEDICINAL CHEMISTRY; METABOLISM; PHARMACOKINETICS; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE;

BIOCOMPATIBLE MATERIALS; BIOLOGICAL AVAILABILITY; BRAIN; CACO-2 CELLS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOPARTICLES; NANOSTRUCTURES; QUERCETIN; TISSUE DISTRIBUTION;

EID: 84992151588     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.10.024     Document Type: Article

References (49)

1. Alam, M.N., Bristi, N.J., Rafiquzzaman, M., Review on in vivo and in vitro methods evaluation of antioxidant activity. Saudi Pharm. J. SPJ 21 (2013), 143–152, 10.1016/j.jsps.2012.05.002.
2. Aslam, A., Misbah, S.A., Talbot, K., Chapel, H., Vitamin E deficiency induced neurological disease in common variable immunodeficiency: two cases and a review of the literature of vitamin E deficiency. Clin. Immunol. Orlando Fla. 112 (2004), 24–29, 10.1016/j.clim.2004.02.001.
3. Aytac, Z., Kusku, S.I., Durgun, E., Uyar, T., Quercetin/β-cyclodextrin inclusion complex embedded nanofibres: slow release and high solubility. Food Chem. 197 (2016), 864–871, 10.1016/j.foodchem.2015.11.051.
4. Bagad, M., Khan, Z.A., Poly(n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats. Int. J. Nanomed. 10 (2015), 3921–3935, 10.2147/IJN.S80706.
5. Beg, S., Sharma, G., Thanki, K., Jain, S., Katare, O.P., Singh, B., Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: systematic development, in vitro, ex vivo and in vivo evaluation. Int. J. Pharm. 493 (2015), 466–482.
6. Behl, C., Moosmann, B., Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds. Biol. Chem. 383 (2002), 521–536, 10.1515/BC.2002.053.
7. http://www.brainfacts.org/, 2016. (last accessed on 07/10/2016).
8. Chen-yu, G., Chun-fen, Y., Qi-lu, L., Qi, T., Yan-wei, X., Wei-na, L., Guang-xi, Z., Development of a quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int. J. Pharm. 430 (2012), 292–298, 10.1016/j.ijpharm.2012.03.042.
9. Cui, B., Feng, L., Wang, C., Yang, D., Yu, M., Zeng, Z., Wang, Y., Sun, C., Zhao, X., Cui, H., Stability and biological activity evaluation of chlorantraniliprole solid nanodispersions prepared by high pressure homogenization. PLoS One, 11, 2016, e0160877, 10.1371/journal.pone.0160877.
10. Díaz, M., Vaamonde, L., Dajas, F., Assessment of the protective capacity of nanosomes of quercetin in an experimental model of parkinsonís disease in the rat, Gen. Med. Gen. Med.: Open Access 3:5 (2015), 1–7.
11. Dhawan, S., Kapil, R., Singh, B., Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J. Pharm. Pharmacol. 63 (2011), 342–351, 10.1111/j.2042-7158.2010.01225.x.
12. Ernsting, M.J., Murakami, M., Roy, A., Li, S.-D., Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J. Control. Release 172 (2013), 782–794, 10.1016/j.jconrel.2013.09.013.
13. Gaucher, G., Asahina, K., Wang, J., Leroux, J.-C., Effect of poly(N-vinyl-pyrrolidone)-block-poly(D, L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. Biomacromolecules 10 (2009), 408–416, 10.1021/bm801178f.
14. Ghosh, A., Sarkar, S., Mandal, A.K., Das, N., Neuroprotective role of nanoencapsulated quercetin in combating ischemia-reperfusion induced neuronal damage in young and aged rats. PLoS One, 8, 2013, e57735, 10.1371/journal.pone.0057735.
15. Gokhale, A., Achieving zero-order release kinetics using multi-step diffusion-based drug delivery. Pharm. Tech., 38(5), 2014.
16. Heo, H.J., Lee, C.Y., Protective effects of quercetin and vitamin C against oxidative stress-induced neurodegeneration. J. Agric. Food Chem. 52 (2004), 7514–7517, 10.1021/jf049243r.
17. Huang, X., Brazel, C.S., On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release 73 (2001), 121–136.
18. Huber, A., Stuchbury, G., Bürkle, A., Burnell, J., Münch, G., Neuroprotective therapies for Alzheimer's disease. Curr. Pharm. Des. 12 (2006), 705–717.
19. Jain, S., Jain, A.K., Pohekar, M., Thanki, K., Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity. Free Radic. Biol. Med. 65 (2013), 117–130, 10.1016/j.freeradbiomed.2013.05.041.
20. Juntachote, T., Berghofer, E., Antioxidative properties and stability of ethanolic extracts of Holy basil and Galangal. Food Chem. 92 (2005), 193–202.
21. Küllenberg, D., Taylor, L.A., Schneider, M., Massing, U., Health effects of dietary phospholipids. Lipids Health Dis., 11, 2012, 3, 10.1186/1476-511X-11-3.
22. Kakkar, V., Kaur, I.P., Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem. Toxicol. 49 (2011), 2906–2913, 10.1016/j.fct.2011.08.006.
23. Katare, O.P., Raza, K., Singh, B., Dogra, S., Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. Indian J. Dermatol. Venereol. Leprol. 76 (2010), 612–621, 10.4103/0378-6323.72451.
24. Korsmeyer, R.W., Gurny, R., Doelker, E., Buri, P., Peppas, N.A., Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm. 15 (1983), 25–35, 10.1016/0378-5173(83)90064-9.
25. Kumar, P., Raza, K., Kaushik, L., Malik, R., Arora, S., Katare, O.P., Role of colloidal drug delivery carriers in taxane-mediated chemotherapy: a review. Curr. Pharm. Des., 22, 2016, 10.2174/1381612822666160524144926.
26. Li, M., Reineke, J., Physiologically based pharmacokinetic modeling for nanoparticle toxicity study. Methods Mol. Biol. Clifton N.J. 926 (2012), 369–382, 10.1007/978-1-62703-002-1_24.
27. Li, H., Zhao, X., Ma, Y., Zhai, G., Li, L., Lou, H., Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control. Release 133 (2009), 238–244, 10.1016/j.jconrel.2008.10.002.
28. Liu, L., Tang, Y., Gao, C., Li, Y., Chen, S., Xiong, T., Li, J., Du, M., Gong, Z., Chen, H., Characterization and biodistribution in vivo of quercetin-loaded cationic nanostructured lipid carriers. Colloids Surf. B Biointerfaces 115 (2014), 125–131.
29. Manach, C., Morand, C., Demigné, C., Texier, O., Régérat, F., Rémésy, C., Bioavailability of rutin and quercetin in rats. FEBS Lett. 409 (1997), 12–16, 10.1016/S0014-5793(97)00467-5.
30. Nanocomposix's guide to dynamic light scattering measurement and analysis. 2016. https://cdn.shopify.com/s/files/1/0257/8237/files/nanoComposix_Guidelines_for_DLS_Measurements_and_Analysis (Last accessed on 05.10.16).
31. Olugbami, J.O., Gbadegesin, M.A., Odunola, O.A., In vitro free radical scavenging and antioxidant properties of ethanol extract of Terminalia glaucescens. Pharmacogn. Res. 7 (2015), 49–56, 10.4103/0974-8490.147200.
32. Raza, K., Singh, B., Singla, N., Negi, P., Singal, P., Katare, O.P., Nano-lipoidal carriers of isotretinoin with anti-aging potential: formulation, characterization and biochemical evaluation. J. Drug Target. 21 (2013), 435–442, 10.3109/1061186X.2012.761224.
33. Raza, K., Singh, B., Singla, S., Wadhwa, S., Garg, B., Chhibber, S., Katare, O.P., Nanocolloidal carriers of isotretinoin: antimicrobial activity against Propionibacterium acnes and dermatokinetic modeling. Mol. Pharm. 10 (2013), 1958–1963, 10.1021/mp300722f.
34. Raza, K., Kumar, M., Kumar, P., Malik, R., Sharma, G., Kaur, M., Katare, O.P., Topical delivery of aceclofenac: challenges and promises of novel drug delivery systems. BioMed Res. Int., 2014, 406731, 10.1155/2014/406731.
35. Raza, K., Thotakura, N., Kumar, P., Joshi, M., Bhushan, S., Bhatia, A., Kumar, V., Malik, R., Sharma, G., Guru, S.K., Katare, O.P., C60-fullerenes for delivery of docetaxel to breast cancer cells: a promising approach for enhanced efficacy and better pharmacokinetic profile. Int. J. Pharm. 495 (2015), 551–559, 10.1016/j.ijpharm.2015.09.016.
36. Raza, K., Kumar, D., Kiran, C., Kumar, M., Guru, S.K., Kumar, P., Arora, S., Sharma, G., Bhushan, S., Katare, O.P., Conjugation of docetaxel with multiwalled carbon nanotubes and codelivery with piperine: implications on pharmacokinetic profile and anticancer activity. Mol. Pharm. 13 (2016), 2423–2432, 10.1021/acs.molpharmaceut.6b00183.
37. Rice-Evans, C.A., Miller, N.J., Bolwell, P.G., Bramley, P.M., Pridham, J.B., The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic. Res. 22 (1995), 375–383.
38. Saxena, V., Sadoqi, M., Shao, J., Indocyanine green-loaded biodegradable nanoparticles: preparation, physicochemical characterization and in vitro release. Int. J. Pharm. 278 (2004), 293–301.
39. Shargel, L., Wu-Pong, S., Yu, A.B., Applied Biopharmaceutics & Pharmacokinetics. 2007, McGraw-Hill.
40. Siepmann, J., Peppas, N.A., Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv. Drug Deliv. Rev. 48:2 (2001), 139–157.
41. Sun, W., Xie, C., Wang, H., Hu, Y., Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 25 (2004), 3065–3071, 10.1016/j.biomaterials.2003.09.087.
42. Thakur, K.T., Albanese, E., Giannakopoulos, P., Jette, N., Linde, M., Prince, M.J., Steiner, T.J., Dua, T., Neurological disorders., third edition Patel, V., Chisholm, D., Dua, T., Laxminarayan, R., Medina-Mora, M.E., (eds.) Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, vol. 4, 2016, The International Bank for Reconstruction and Development/The World Bank, Washington (DC).
43. Thotakura, N., Dadarwal, M., Kumar, P., Sharma, G., Guru, S.K., Bhushan, S., Raza, K., Katare, O.P., Chitosan-stearic acid based polymeric micelles for the effective delivery of tamoxifen: cytotoxic and pharmacokinetic evaluation. AAPS PharmSciTech, 2016, 10.1208/s12249-016-0563-6.
44. Uttara, B., Singh, A.V., Zamboni, P., Mahajan, R., Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7 (2009), 65–74, 10.2174/157015909787602823.
45. Wach, A., Pyrzyńska, K., Biesaga, M., Quercetin content in some food and herbal samples. Food Chem. 100 (2007), 699–704.
46. Wang, S., Su, R., Nie, S., Sun, M., Zhang, J., Wu, D., Moustaid-Moussa, N., Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals. J. Nutr. Biochem. 25 (2014), 363–376, 10.1016/j.jnutbio.2013.10.002.
47. WCN, High Global Burden of Neurological Diseases Recognized. 2015 (last accessed 16.10.16.) https://www.wfneurology.org/wcn-2015-high-global-burden-of-neurological-disease.
48. Yadav, H., Kumar, P., Sharma, V., Sharma, G., Raza, K., Katare, O.P., Enhanced efficacy and a better pharmacokinetic profile of tamoxifen employing polymeric micelles. RSC Adv. 6:58 (2016), 53351–53357.
49. Zandi, P.P., Anthony, J.C., Khachaturian, A.S., Stone, S.V., Gustafson, D., Tschanz, J.T., Norton, M.C., Welsh-Bohmer, K.A., Breitner, J.C.S., Cache County Study Group, Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 61 (2004), 82–88, 10.1001/archneur.61.1.82.